A new study published online October 11, 2023 in Nature highlights the vast array of functional diversity of microbes through a novel approach to better understand microbial communities by looking at protein function within them. […]
On October 5th, 2023, the European Medical Agency adopted guidelines on the quality, safety, and efficacy of veterinary medicinal products (VMPs) designed for phage therapy. The aim of the guidelines is to provide clear “regulatory/technical […]
Senior Fonterra Managers Dr Mark Malone and Dr Shalome Bassett were in Ireland to launch the ‘Fonterra Microbiome Research Centre (Ireland)’, their new collaboration with APC Microbiome Ireland (APC), a world renowned SFI Research Centre […]
INTRODUCTION Every corner of the human body is inhabited by microbes, collectively known as the microbiome. Thousands of publications over the last decade have described how these microorganisms influence human physiology, health and disease, and […]
Lallemand Health Solutions is strengthening its strategic position in the microbiome field through contract development and manufacturing operations, with the launch of Expert’Biome™ CDMO by Lallemand. With Expert’Biome™, Lallemand Health Solutions aims to support partners […]
Researchers have discovered the link between the gut microbiota and Alzheimer’s disease. For the first time, researchers have found that Alzheimer’s symptoms can be transferred to a healthy young organism via the gut microbiota, confirming […]
Kanvas Biosciences, announced it acquired two active therapeutics programs, a microbial library, and intellectual property from Federation Bio, a manufacturer of live biotherapeutics products (LBPs). This acquisition transitions Kanvas Biosciences from a technology company with […]
Clinical Microbiomics A/S, a leading innovator in bioinformatics and systems biology for the microbiome field based in Copenhagen, Denmark, announces the merger with CosmosID Inc, a leading CLIA-certified, GxP-compliant microbiome CRO based in Germantown, Maryland, United States. Clinical Microbiomics and […]
Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that the first patient in the Phase 2 COLLECTiVE202 clinical study of VE202 […]